Protagonist Therapeutics, Inc. (PTGX)

Market Cap	3.45B
Revenue (ttm)	207.80M
Net Income (ttm)	56.19M
Shares Out	61.98M
EPS (ttm)	0.86
PE Ratio	64.57
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,257,709
Open	55.34
Previous Close	55.22
Day's Range	54.71 - 55.90
52-Week Range	31.34 - 60.60
Beta	2.25
Analysts	Strong Buy
Price Target	67.11 (+20.51%)
Earnings Date	Aug 5, 2025

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 126
• Stock Exchange: NASDAQ
• Ticker Symbol: PTGX
• Website: https://www.protagonist-inc.com

Analyst Forecast

According to 9 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price forecast is $67.11, which is an increase of 20.51% from the latest price.

Price Target

$67.11

(20.51% upside)

Analyst Consensus: Strong Buy